,feature,Maximum hospitalization rate | corr,Maximum hospitalization rate | p-value,If hospitalization threshold passed | corr,If hospitalization threshold passed | p-value
0,Obs: Incidence rate,0.32726175967412297,2.1595740090294295e-26,0.2613797120591336,4.400789503584523e-17
1,Obs: Incidence rate-ave-2wk,0.32501313299381634,4.9317387300279915e-26,0.25206170770256237,5.872692384030407e-16
2,Obs: Incidence rate-slope-4wk,0.2010934064007858,1.3913389789437604e-10,0.1406059041756978,8.08288616690399e-06
3,Obs: New hospitalization rate,0.40028689953513846,8.990166917761984e-40,0.19037285050292105,1.2937885288697514e-09
4,Obs: New hospitalization rate-ave-2wk,0.3962164577138918,6.211689214406452e-39,0.190084239678973,1.3714476827391073e-09
5,Obs: New hospitalization rate-slope-4wk,0.2418144427003658,9.001739996797646e-15,0.08770698758840247,0.005513054256624169
6,Obs: % of incidence due to Novel-Unvaccinated,0.32710913695618987,2.2845742576923984e-26,0.286916648379944,2.101184218580917e-20
7,Obs: % of incidence due to Novel-Unvaccinated-ave-2wk,0.3205621112344874,2.4775906051618764e-25,0.28105275516951855,1.3071008541936921e-19
8,Obs: % of incidence due to Novel-Unvaccinated-slope-4wk,0.36204274197849523,2.470873113605496e-32,0.31447157888763005,2.159580300620377e-24
9,Obs: % of incidence due to Novel-Vaccinated,0.18235357088138293,6.319386134836774e-09,0.21879658581270436,2.648285758361382e-12
10,Obs: % of incidence due to Novel-Vaccinated-ave-2wk,0.17696373114548788,1.7648139908331552e-08,0.2163258655632677,4.701792828889934e-12
11,Obs: % of incidence due to Novel-Vaccinated-slope-4wk,0.2254392496099362,5.467155938237114e-13,0.2543229472494011,3.161731464925688e-16
12,Obs: % of new hospitalizations due to Novel-Unvaccinated,0.25640736043503,1.7769713516284232e-16,0.21624017712416427,4.795740822892122e-12
13,Obs: % of new hospitalizations due to Novel-Unvaccinated-ave-2wk,0.2759703398345068,6.154001158929383e-19,0.23158277127291682,1.2147752438552213e-13
14,Obs: % of new hospitalizations due to Novel-Unvaccinated-slope-4wk,0.13772119203857616,1.2395039238838514e-05,0.13837870732723642,1.1252496051884368e-05
15,Obs: % of new hospitalizations due to Novel-Vaccinated,0.06306991718088711,0.04615896628542865,0.09786155699153251,0.0019468494619849345
16,Obs: % of new hospitalizations due to Novel-Vaccinated-ave-2wk,0.08594898524062451,0.006536488211096325,0.1013598742576298,0.001329471553309049
17,Obs: % of new hospitalizations due to Novel-Vaccinated-slope-4wk,0.017824572699107394,0.5734333699781735,0.05112768463060627,0.10613019861930575
18,Obs: % of incidence with novel variant,0.30243603971174643,1.3467906246690987e-22,0.28744096928285995,1.7805769045584702e-20
19,Obs: % of incidence with novel variant-ave-2wk,0.2942299126648287,2.0219823932393847e-21,0.2809656121914875,1.3426544469002532e-19
20,Obs: % of incidence with novel variant-slope-4wk,0.3538987507128949,7.11053322713983e-31,0.32906266182959815,1.109081525403464e-26
21,Obs: % of new hospitalizations with novel variant,0.25653823181888963,1.7135346406518657e-16,0.23090309894192626,1.437799026690706e-13
22,Obs: % of new hospitalizations with novel variant-ave-2wk,0.2743942095567565,9.884885632766562e-19,0.23859597618300205,2.0680224995772457e-14
23,Obs: % of new hospitalizations with novel variant-slope-4wk,0.13761713623443325,1.258568986626827e-05,0.14966496613446365,1.9972646734357578e-06
24,Obs: Prevalence susceptible,0.18442460091711915,4.2235825276963226e-09,0.12197384572551495,0.00011028468996361732
25,Obs: Cumulative vaccination rate,-0.18501086058436822,3.76512155438397e-09,-0.19743768474656107,3.0187711044139344e-10
26,Obs: Cumulative hospitalization rate,0.437874770814067,4.2522678834702515e-48,0.2185068453880094,2.8337107963577175e-12
27,R0,0.025048089221608838,0.42881353085381363,0.006685275198353616,0.8327741948774714
28,Duration of infectiousness-dominant,0.0012169016446818368,0.9693418975799469,0.04535246056326725,0.1518251436031972
29,Prob Hosp for 18-29,0.03140064863259782,0.3212080737810766,0.050021615792083925,0.11391607919961687
30,Relative prob hosp by age-0,0.03318756404000716,0.29442712343401306,-0.005788804355667605,0.8549309030676182
31,Relative prob hosp by age-1,-0.0037505583687706913,0.905707032428991,0.020034303550469406,0.5268567881709845
32,Relative prob hosp by age-2,0.049171996002167706,0.12019627401615578,-0.025583238061136934,0.41901376841999766
33,Relative prob hosp by age-4,-0.01674706892236913,0.5968307375392374,0.034207139469582114,0.27983589352508853
34,Relative prob hosp by age-5,0.034109005173131146,0.2812185737882139,0.05626702272183043,0.07532125420596791
35,Relative prob hosp by age-6,0.048782352610448186,0.12316549877066894,0.0879743284055954,0.005370756844386513
36,Relative prob hosp by age-7,0.060390797470910744,0.05625192792741736,0.08049029335992396,0.01088792605662847
37,Ratio of hospitalization probability by profile-1,0.03733453625586019,0.2381767279109633,-0.009773603705446348,0.7575578830684507
38,Ratio of hospitalization probability by profile-2,0.0030285232501819437,0.9237979559082706,-0.0065449266276256055,0.83623470185986
39,Ratio transmissibility by profile-1,0.01131084021815229,0.7209089668928048,0.003173161429972534,0.9201705217546179
40,Ratio transmissibility by profile-2,-0.04367929614510757,0.16752760219356705,0.007572323705156606,0.8109800952834729
41,Ratio of infectiousness duration by profile-1,0.04078819581827129,0.19748184693622697,-0.028666751967732267,0.36516106067243037
42,Ratio of infectiousness duration by profile-2,0.031263947666366095,0.3233202992962955,0.025114679014722436,0.42758692313979
43,Duration of R-0,-0.02043652643442726,0.5185910166907318,-0.02846412639501295,0.3685615281647107
44,Duration of R-1,0.06691712557314435,0.03435921943938525,-0.0014611371243885953,0.9631927284379562
45,Duration of R-2,0.001956620193436546,0.9507249419644419,-0.019611274815656946,0.5356220030227457
46,Duration of vaccine immunity,-0.05107528123055327,0.10648931533275355,0.03962048727393492,0.21063024070356914
47,Prob novel strain params-0,-0.019467463237988144,0.5386184184790156,-0.023378032796624898,0.4602382455863596
48,Prob novel strain params-1,-0.06746269379105925,0.03291488620853368,-0.0346743651135961,0.2733161667775377
49,Prob novel strain params-2,0.016155802724850423,0.6098513466678391,0.0398959527520215,0.20747291867598167
50,Vaccine effectiveness against infection with novel,0.018856867601985197,0.5514333512955717,-0.02502546819075925,0.42923068277517645
51,PD Y1 thresholds-0,0.015702313894179334,0.6199224246446677,-0.014857893224155566,0.6388651539024536
52,PD Y1 thresholds-1,-0.017544485672863826,0.5794733908294927,0.04435594374152524,0.1610366353628848
53,Change in contacts - PD Y1,-0.011147719371451896,0.7247693627353463,-0.01746023646925702,0.5812960224280488
54,Change in contacts - PD Y1+,-0.03443488522461295,0.2766448310405161,-0.04192150317295906,0.18530432162352045
